Month: May 2025

InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update

Written by Customer Service on May 7, 2025. Posted in Earnings Releases And Operating Results.

Announces successful completion of sub-chronic and chronic toxicology studies for INF904, supporting long-term dosing in future clinical trials Multiple near-term catalysts anticipated with the potential to substantially de-risk the Company’s pipeline addressing multiple sizable markets Interim analysis for vilobelimab Phase 3 trial in pyoderma gangrenosum (PG), to determine trial size adaptation or futility, remains on schedule with a recommendation expected to be announced at the end of May to early June Topline data for INF904 Phase 2a trial in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected in summer 2025 Cash, cash equivalents and marketable securities totaled €65.7 million on March 31, 2025, including proceeds from our underwritten public offering completed in February Company estimates it has...

Costamare Inc. Announces Completion of the Costamare Bulkers Holdings Limited Spin-Off

Written by Customer Service on May 7, 2025. Posted in Public Companies.

MONACO , May 07, 2025 (GLOBE NEWSWIRE) — Costamare Inc. (NYSE:CMRE) (the “Company”) announced today that it has completed the spin-off of its dry bulk business into a standalone public company, Costamare Bulkers Holdings Limited (“Costamare Bulkers”). Each holder of Costamare Inc. common shares received one common share of Costamare Bulkers Holdings Limited for every five Costamare Inc. common shares held as of the close of business on April 29, 2025. The successful execution of the Costamare Bulkers spin-off transforms Costamare Inc. into a predominantly global container shipping provider, while still maintaining its presence in Neptune Maritime Leasing. Costamare Bulkers shares will be listed and commence trading today on the NYSE under the ticker symbol “CMDB” from 9:30 a.m., New York City time. Costamare Inc. will continue...

Costamare Bulkers Holdings Limited Debuts as Independent, Publicly Traded Company

Written by Customer Service on May 7, 2025. Posted in Public Companies.

Company completes separation from Costamare Inc. Begins trading today on NYSEMONACO, May 07, 2025 (GLOBE NEWSWIRE) — Costamare Bulkers Holdings Limited (NYSE:CMDB) (“Costamare Bulkers” or the “Company”) announced today its debut as an independent, publicly traded company and the completion of its separation from Costamare Inc. The Company’s shares begin trading today from 9:30 a.m., New York City time on the New York Stock Exchange (the “NYSE”) under the symbol “CMDB.” Costamare Inc. will continue to trade on the NYSE under the ticker symbol “CMRE.” Under the terms of the separation, each holder of Costamare Inc. common shares received one common share of Costamare Bulkers for every five Costamare Inc. common shares held as of the close of business on April 29, 2025. Following the successful execution of the spin-off, the Company...

Sunrise Realty Trust, Inc. Announces Financial Results for the First Quarter 2025

Written by Customer Service on May 7, 2025. Posted in Earnings Releases And Operating Results.

First quarter 2025 GAAP net income of $3.1 million or $0.27 per basic weighted average common share and Distributable Earnings(1) of $3.5 million or $0.31 per basic weighted average common share WEST PALM BEACH, Fla., May 07, 2025 (GLOBE NEWSWIRE) — Sunrise Realty Trust, Inc. (NASDAQ:SUNS) (“SUNS” or the “Company”) today announced its results for the quarter ended March 31, 2025. SUNS reported generally accepted accounting principles (“GAAP”) net income of $3.1 million or $0.27 per basic weighted average common share and Distributable Earnings of $3.5 million or $0.31 per basic weighted average common share for the first quarter of 2025. Brian Sedrish, Chief Executive Officer, said, “SUNS entered 2025 with a strong balance sheet and a portfolio comprised of recently originated, performing loans, enabling the Company to continue...

BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025

Written by Customer Service on May 7, 2025. Posted in Public Companies.

PALO ALTO, Calif., May 07, 2025 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will participate in a fireside chat at the Bank of America Merrill Lynch Global Healthcare Conference 2025 in Las Vegas, NV on Wednesday, May 14 at 2:20 pm PT. To access the live webcast of BridgeBio’s presentation, please visit the “Events” page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcast will be available on the BridgeBio website for 30 days following the event. About BridgeBio Pharma, Inc.BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative...

250 MW/1,000 MWh Oneida Energy Storage Project Commences Commercial Operations

Written by Customer Service on May 7, 2025. Posted in Public Companies.

Provides Ontario with critical capacity as Canada’s largest grid-scale battery energy storage facility in operationOneida Battery Energy Storage Project, April 2025 TORONTO, May 07, 2025 (GLOBE NEWSWIRE) — The Oneida Energy Storage Project (“Oneida”) has officially entered commercial operations, becoming the largest battery energy storage facility in operations in Canada, and one of the largest globally. Located in Haldimand County, Ontario, the 250 MW / 1,000 MWh facility was delivered ahead of schedule and under budget through a collaborative partnership between majority owner Northland Power Inc. (Northland), Six Nations of the Grand River Development Corporation (SNGRDC), NRStor Inc., Aecon Concessions, and the Mississaugas of the Credit Business Corporation (MCBC). Together, they form the Oneida Energy Storage Limited Partnership...

YY Group Holding Limited Announces Global Expansion Across Europe, Middle East, North Africa, and Asia-Pacific

Written by Customer Service on May 7, 2025. Posted in Mergers And Acquisitions.

Singapore, May 07, 2025 (GLOBE NEWSWIRE) — YY Group Holding Limited (NASDAQ: YYGH) (“YY Group,” “YYGH,” or the “Company”) is thrilled to announce a significant milestone as its flagship on-demand job matching platform, YY Circle, continues to expand its footprint, meeting the surging global demand for innovative workforce solutions. Driving Innovation Across Europe In Europe, YY Circle is making significant strides:YY Circle UK, based in London, is gaining momentum, serving an impressive portfolio of clients and solidifying its position as a trusted partner for businesses in the region. YY Circle Netherlands is on track to go live by the end of this May, marking a pivotal step in expanding YY Circle’s presence in Northern Europe. YY Circle Germany is poised to launch within 6 to 8 weeks, reinforcing YY Group’s commitment to delivering...

Sprott Announces First Quarter 2025 Results

Written by Customer Service on May 7, 2025. Posted in Earnings Releases And Operating Results.

TORONTO, May 07, 2025 (GLOBE NEWSWIRE) — Sprott Inc. (NYSE/TSX: SII) (“Sprott” or the “Company”) today announced its financial results for the quarter ended March 31, 2025. Management commentary “Sprott’s Assets Under Management (“AUM”) ended the first quarter of 2025 at $35.1 billion, up 11% from $31.5 billion as at December 31, 2024,” said Whitney George, Chief Executive Officer of Sprott. “Our AUM growth during the quarter was driven by surging gold prices and strong inflows to our physical gold and silver strategies. During the first three months of the year, we benefited from over $3.1 billion of market value appreciation. We also delivered approximately $407 million of net flows. Subsequent to quarter-end, we generated another $816 million of net flows, primarily into our flagship Sprott Physical Gold Trust...

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Written by Customer Service on May 7, 2025. Posted in Earnings Releases And Operating Results.

Updated Cemsidomide Multiple Myeloma Data Further Demonstrate Compelling Response Rates at Multiple Doses and Potential for Best-in-Class Profile; 50% ORR Observed at the Highest Dose Level of 100 µg, Including One Patient With a Minimal Residual Disease Negative Complete Response; 40% ORR Achieved at the 75 µg Dose Level Cemsidomide Multiple Myeloma Dose Escalation is Complete; FDA Feedback Expected by Mid-Year 2025 to Support Initiation of Next Phase of Development in Early 2026 Portfolio Decision to Prioritize Cemsidomide Development; C4T to Seek Partnership Opportunities to Advance BRAF Program CFT8919 Phase 1 Trial Continues to Advance in Partnership with Betta Pharmaceuticals; Discovery Platform Achieves Two Preclinical Milestones Under the Roche Collaboration Cash, Cash Equivalents and Marketable Securities of $234.7 Million...

Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update

Written by Customer Service on May 7, 2025. Posted in Earnings Releases And Operating Results.

— First quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $37.7 million — — Setmelanotide pivotal Phase 3 TRANSCEND trial met primary endpoint with -19.8% placebo-adjusted BMI reduction in patients (N=120) with acquired hypothalamic obesity — — U.S. and EU regulatory submissions for setmelanotide in acquired hypothalamic obesity on track to be completed in the third quarter of 2025 — — Topline data from Phase 2 trial of oral MC4R agonist bivamelagon on track to be announced in third quarter of 2025 — — Cash on-hand expected to support planned operations into 2027 — — Management to host conference call today at 8:00 a.m. ET — BOSTON, May 07, 2025 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage...

Month: May 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals